title: Is slow-onset long-acting monoamine transport blockade to cocaine as methadone is to heroin? Implication for anti-addiction medications.
abstract: The success of methadone in treating opiate addiction has suggested that long-acting agonist therapies may be similarly useful for treating cocaine addiction. Here, we examined this hypothesis, using the slow-onset long-acting monoamine reuptake inhibitor 31,345, a trans-aminotetralin analog, in a variety of addiction-related animal models, and compared it with methadone's effects on heroin's actions in the same animal models. Systemic administration of 31,345 produced long-lasting enhancement of electrical brain-stimulation reward (BSR) and extracellular nucleus accumbens (NAc) dopamine (DA). Pretreatment with 31,345 augmented cocaine-enhanced BSR, prolonged cocaine-enhanced NAc DA, and produced a long-term (24-48  h) reduction in cocaine self-administration rate without obvious extinction pattern, suggesting an additive effect of 31,345 with cocaine. In contrast, methadone pretreatment not only dose-dependently inhibited heroin self-administration with an extinction pattern but also dose-dependently inhibited heroin-enhanced BSR and NAc DA, suggesting functional antagonism by methadone of heroin's actions. In addition, 31,345 appears to possess significant abuse liability, as it produces dose-dependent enhancement of BSR and NAc DA, maintains a low rate of self-administration behavior, and dose-dependently reinstates drug-seeking behavior. In contrast, methadone only partially maintains self-administration with an extinction pattern, and fails to induce reinstatement of drug-seeking behavior. These findings suggest that 31,345 is a cocaine-like slow-onset long-acting monoamine transporter inhibitor that may act as an agonist therapy for cocaine addiction. However, its pattern of action appears to be significantly different from that of methadone. Ideal agonist substitutes for cocaine should fully emulate methadone's actions, that is, functionally antagonizing cocaine's action while blocking monoamine transporters to augment synaptic DA.
authors.affiliation: Intramural Research Program, National Institute on Drug Abuse, NIH, DHHS, Baltimore, MD 21224, USA.
authors.forename: Xiao-Qing
authors.initials: XQ
authors.lastname: Peng
authors.forename: Zheng-Xiong
authors.initials: ZX
authors.lastname: Xi
authors.forename: Xia
authors.initials: X
authors.lastname: Li
authors.forename: Krista
authors.initials: K
authors.lastname: Spiller
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.forename: Lauren
authors.initials: L
authors.lastname: Chun
authors.forename: Kuo-Ming
authors.initials: KM
authors.lastname: Wu
authors.forename: Mark
authors.initials: M
authors.lastname: Froimowitz
authors.forename: Eliot L
authors.initials: EL
authors.lastname: Gardner
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects; D003042:Cocaine / Q000494:pharmacology*; D019970:Cocaine-Related Disorders / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation / Q000379:methods; D005108:Extinction, Psychological / Q000187:drug effects; D003932:Heroin / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D008297:Male; D008691:Methadone / Q000494:pharmacology*; D009714:Nucleus Accumbens / Q000378:metabolism; D050480:Plasma Membrane Neurotransmitter Transport Proteins / Q000037:antagonists & inhibitors*; D051381:Rats; D020318:Rats, Long-Evans; D012646:Self Administration; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: C556220:(4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl)dimethylammonium; D003692:Delayed-Action Preparations; D050480:Plasma Membrane Neurotransmitter Transport Proteins; D013764:Tetrahydronaphthalenes; D003932:Heroin; D003042:Cocaine; D008691:Methadone; D004298:Dopamine
references.citation: J Pharmacol Exp Ther. 2001 Jul;298(1):1-6
references.pmid: 11408518
references.citation: Addict Behav. 2007 Oct;32(10):2140-50
references.pmid: 17360126
references.citation: Neuropsychopharmacology. 2006 Jul;31(7):1393-405
references.pmid: 16205781
references.citation: Neurosci Biobehav Rev. 1999 May;23(5):717-41
references.pmid: 10392662
references.citation: J Neurosci. 2005 Feb 23;25(8):1889-93
references.pmid: 15728828
references.citation: Mol Pharmacol. 1998 Mar;53(3):377-84
references.pmid: 9495801
references.citation: J Biol Chem. 2001 Aug 3;276(31):29012-8
references.pmid: 11395483
references.citation: J Neurochem. 2010 Jan;112(2):564-76
references.pmid: 19895667
references.citation: Psychopharmacology (Berl). 2009 Dec;207(2):281-9
references.pmid: 19756525
references.citation: Drug Alcohol Depend. 1995 May;38(2):95-137
references.pmid: 7671769
references.citation: Br J Psychiatry. 2008 Jul;193(1):65-72
references.pmid: 18700222
references.citation: Addiction. 2005 Oct;100(10):1496-509
references.pmid: 16185211
references.citation: Neuropsychopharmacology. 2004 Jul;29(7):1312-20
references.pmid: 15039768
references.citation: Mol Pharmacol. 2002 Feb;61(2):436-45
references.pmid: 11809869
references.citation: Arch Intern Med. 1966 Oct;118(4):304-9
references.pmid: 4162686
references.citation: Trends Pharmacol Sci. 1996 Jul;17(7):260-4
references.pmid: 8756185
references.citation: Am J Addict. 2000 Fall;9(4):285-313
references.pmid: 11155784
references.citation: Pharmacol Biochem Behav. 1992 Mar;41(3):489-96
references.pmid: 1584830
references.citation: Behav Pharmacol. 1990;1(4):355-363
references.pmid: 11175420
references.citation: Alcohol Alcohol. 2002 Sep-Oct;37(5):485-94
references.pmid: 12217944
references.citation: JAMA. 1965 Aug 23;193:646-50
references.pmid: 14321530
references.citation: Biochem Biophys Res Commun. 2002 Feb 8;290(5):1545-50
references.pmid: 11820798
references.citation: J Biol Chem. 2007 Dec 7;282(49):35842-54
references.pmid: 17923483
references.citation: Psychopharmacology (Berl). 1977 Oct 20;54(2):109-12
references.pmid: 412203
references.citation: Mol Pharmacol. 2002 Dec;62(6):1464-70
references.pmid: 12435815
references.citation: Mol Pharmacol. 2007 May;71(5):1222-32
references.pmid: 17267664
references.citation: J Med Chem. 1996 Nov 22;39(24):4689-91
references.pmid: 8941381
references.citation: J Neurosci. 2003 Apr 15;23(8):3498-505
references.pmid: 12716959
references.citation: Curr Opin Neurobiol. 1996 Apr;6(2):243-51
references.pmid: 8725967
references.citation: Science. 1997 Oct 3;278(5335):66-70
references.pmid: 9311929
references.citation: J Med Chem. 2000 Dec 28;43(26):4981-92
references.pmid: 11150168
references.citation: J Biol Chem. 2003 Jun 13;278(24):22168-74
references.pmid: 12682063
references.citation: Mol Pharmacol. 2001 Jan;59(1):113-21
references.pmid: 11125031
references.citation: J Pharmacol Exp Ther. 2003 Nov;307(2):729-36
references.pmid: 12975490
references.citation: Clin Psychol Rev. 2010 Mar;30(2):155-66
references.pmid: 19926374
references.citation: Neuropharmacology. 2006 Oct;51(5):993-1003
references.pmid: 16901516
references.citation: Eur J Pharmacol. 2004 Feb 23;486(3):251-7
references.pmid: 14985046
references.citation: J Med Chem. 1984 Nov;27(11):1508-15
references.pmid: 6492080
references.citation: Med Res Rev. 2002 Sep;22(5):429-64
references.pmid: 12210554
references.citation: NIDA Res Monogr. 1992;120:13-25
references.pmid: 1501682
references.citation: J Med Chem. 2007 Jan 25;50(2):219-32
references.pmid: 17228864
references.citation: Mol Pharmacol. 2008 Mar;73(3):813-23
references.pmid: 17978168
references.citation: J Neurochem. 1999 Feb;72(2):585-93
references.pmid: 9930730
references.citation: Addict Behav. 2004 Sep;29(7):1439-64
references.pmid: 15345275
references.citation: Psychopharmacology (Berl). 2002 May;161(2):202-12
references.pmid: 11981600
references.citation: Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6850-5
references.pmid: 10823899
references.citation: Curr Top Med Chem. 2006;6(17):1825-43
references.pmid: 17017960
references.citation: Psychopharmacology (Berl). 2008 Mar;196(4):533-42
references.pmid: 17985117
references.citation: Eur J Neurosci. 2005 Jun;21(12):3427-38
references.pmid: 16026480
references.citation: Psychopharmacology (Berl). 2002 Oct;163(3-4):265-82
references.pmid: 12373428
references.citation: Clin Pharmacokinet. 1986 Mar-Apr;11(2):144-53
references.pmid: 3514044
references.citation: Mol Neurobiol. 1995 Aug-Dec;11(1-3):1-19
references.pmid: 8561954
references.citation: Biochem Pharmacol. 2008 Jan 1;75(1):2-16
references.pmid: 17897630
references.citation: Mol Pharmacol. 2006 Aug;70(2):542-8
references.pmid: 16684900
references.citation: Neuropharmacology. 2004;47 Suppl 1:80-91
references.pmid: 15464127
references.citation: Arch Gen Psychiatry. 1995 Jun;52(6):456-63
references.pmid: 7771915
references.citation: AAPS J. 2006 Mar 24;8(1):E196-203
references.pmid: 16584128
references.citation: Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9333-8
references.pmid: 16754872
references.citation: Ann N Y Acad Sci. 2000;909:186-216
references.pmid: 10911931
references.citation: J Neurochem. 2007 Apr;101(2):377-88
references.pmid: 17250655
references.citation: Neurosci Biobehav Rev. 2004 Jan;27(8):739-49
references.pmid: 15019424
references.citation: Neurosci Lett. 1987 Aug 31;79(3):315-20
references.pmid: 2958724